Skip to main content

Search

Reset all filters
648 Result(s)
Sort by

"To join Boehringer Ingelheim was the best ever decision"

"To join Boehringer Ingelheim was the best ever decision"

Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Candice is moving to Germany

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Solidarity with Ukraine

Solidarity with Ukraine

Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations
2019 performance

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Non-small cell lung cancer

Non-small cell lung cancer

Discover more about non-small cell lung cancer, including its symptoms and treatment options.
AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D